Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that its …
Read Full Story at source (may require registration)
Latest posts by CHF Editor (see all)
- Technical talk: EUR/CHF rejecting monthly resistance - January 24, 2024
- USD/CHF moves higher to near 0.8680 as Fed members maintain a hawkish stance - January 24, 2024
- Holcim price target lowered by CHF 2 at Barclays - January 24, 2024